[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100629767":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":32,"centralContacts":33,"locations":39,"responsibleParty":60,"collaborators":32,"id":62,"slug":32,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":32,"eligibilityCriteria":67,"healthyVolunteers":68,"sex":69,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":32,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":42,"whyStopped":32,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"ModernaTX, Inc.","INDUSTRY",[8,14,18,22],{"label":9,"type":10,"description":11,"interventionNames":12},"mRNA-1189 Dose Level 1 (ID)","EXPERIMENTAL","Participants will receive 2 intradermal (ID) injections of mRNA-1189 at Dose Level 1 on Days 1 and 57.",[13],"Biological: mRNA-1189",{"label":15,"type":10,"description":16,"interventionNames":17},"mRNA-1189 Dose Level 2 (ID)","Participants will receive 2 ID injections of mRNA-1189 at Dose Level 2 on Days 1 and 57.",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"mRNA-1189 Dose Level 1 (IM)","Participants will receive 2 intramuscular (IM) injections of mRNA-1189 at Dose Level 1 on Days 1 and 57.",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"mRNA-1189 Dose Level 2 (IM)","Participants will receive 2 IM injections of mRNA-1189 at Dose Level 2 on Days 1 and 57.",[13],[27],{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"BIOLOGICAL","mRNA-1189","Sterile liquid for injection",[9,19,15,23],null,[34],{"name":35,"role":36,"phone":37,"phoneExt":32,"email":38},"Moderna WeCare Team","CONTACT","1-866-663-3762","WeCareClinicalTrials@modernatx.com",[40,53],{"facility":41,"status":42,"city":43,"state":44,"zip":45,"country":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":32},"Nucleus Network","RECRUITING","Melbourne","Victoria","VIC 3004","Australia",{"type":48,"coordinates":49},"Point",[50,51],144.96332,-37.814,{"lat":51,"lon":50},{"facility":54,"status":55,"city":43,"state":44,"zip":56,"country":46,"cosmosGeoPoint":57,"geoPoint":59,"contacts":32},"Doherty Clinical Trials","NOT_YET_RECRUITING","VIC 3149",{"type":48,"coordinates":58},[50,51],{"lat":51,"lon":50},{"type":61,"investigatorFullName":32,"investigatorTitle":32,"investigatorAffiliation":32,"oldNameTitle":32,"oldOrganization":32},"SPONSOR","100629767",false,"NCT07478952","A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189 in Healthy Adults 18 to 30 Years of Age","A Phase 1, Randomized, Open-label Study to Evaluate Safety, Reactogenicity, and Immunogenicity of an Epstein-Barr Virus Candidate Vaccine, mRNA-1189, Following Intradermal and Intramuscular Delivery in Healthy Adults 18 to 30 Years of Age","Inclusion Criteria:\n\n* Healthy as determined by medical evaluation including medical history and physical examination.\n* Participants who are assigned female at birth or could become pregnant are eligible to participate if the participant is not pregnant or breast\u002Fchest feeding.\n\nExclusion Criteria:\n\n* Have undergone surgical procedures within 7 days prior to Day 1 or Day 57 or are scheduled to undergo a surgical procedure within 28 days after study intervention administration.\n* Reported history of congenital or acquired immunodeficiency, immunosuppressive condition, asplenia, or recurrent severe infectious disease.\n* Received corticosteroids at ≥10 milligrams per day (mg\u002Fday) of prednisone or equivalent for \\>14 days in total within 90 days prior to Day 1 or is anticipating the need for corticosteroids at any time during the study.\n* Received systemic immunosuppressive treatment, including long-acting biological therapies that affect immune responses, within 180 days prior to Day 1 or plans to do so during the study.\n* Received or plans to receive any nonstudy vaccine from 28 days prior to first dose\u002FDay 1 up to 28 days after the second dose\u002FDay 57.\n* History of myocarditis, pericarditis, or myopericarditis prior to Day 1.\n* Has previously received an investigational EBV vaccine.\n\nNote: Other inclusion and exclusion criteria may apply.",true,"ALL","18 Years","30 Years",{"count":73,"type":74},120,"ESTIMATED","INTERVENTIONAL",[77],"PHASE1","The main objective of this trial is to evaluate the safety and immunogenicity of mRNA-1189 after intradermal and intramuscular delivery.",[80],"Epstein-Barr Virus",[82],"Epstein-Barr Virus (EBV)","2026-03-20",{"date":85,"type":86},"2026-03-24","ACTUAL",{"date":88,"type":86},"2026-03-17",{"date":90,"type":74},"2027-05-15",{"name":5,"class":6},2]